1)Tipnis SR, et al:A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:332-338, 2000
2)Yusuf S, et al:Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:45-153, 2000
3)Pfeffer MA, et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction;Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327:669-677, 1992
4)Dahlof B, et al:Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE);a randomized trial against atenolol. Lancet 359:995-1003, 2002
5)Julius S, et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine;The VALUE randomized trial. Lancet 363:2022-2031, 2004
6)Nussberger J, et al:Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100);Comparison with enalapril. Hypertension 39:E1-8, 2002